Multidrug resistant strains of P.falciparum and P.vivax are becoming increasingly prevalent in the Asia Pacific rim. To determine the efficacy of locally recommended antimalarial protocols in Papua, Indonesia, consecutive patients presenting to a rural clinic were enrolled into a prospective efficacy study. Patients with uncomplicated falciparum malaria were treated with chloroquine plus sulfadoxine-pyrimethamine and those with vivax malaria with chloroquine monotherapy. Patients failing therapy received unsupervised oral quinine +/- doxycycline for 7 days. Follow-up was continued for 42 days for falciparum malaria and 28 days for vivax malaria.

The study hypothesis was that current recommended antimalarial protocols were no longer effective.

Condition	Intervention
Falciparum Malaria Vivax Malaria	Drug: Chloroquine and sulphadoxine-pyrimethamine

Further Study Details: 

Primary Outcomes: • 42 day cure rate; corrected for reinfection by PCR genotyping.; • Overall Cure Rate at Day 42
Secondary Outcomes: • Overall day 28 cure rate for P.falciparum. This will allow comparison with previous historical data at this time point.; • Parasite reduction. Parasite reduction will be calculated at Days 1, 2 and 3 after initiation of trial treatment as percentage of parasites/uL compared to parasite density before the first dose of treatment.; • Proportion of patients with a negative slide at Days 1, 2 and 3; • Gametocyte Carriage. Anti-gametocyte activity will be measured by the proportion of patients with a peripheral gametocytaemia between day 7 to day 28.; • Early Treatment Failure (ETF); • Late Treatment Failure (LTF)
Expected Total Enrollment:  150

Ages Eligible for Study:  12 Months and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

-Male and female patients at least one 1year of age and weighing more than 10kg.

• -Microscopic confirmation of P. falciparum and /or P.vivax infection (any parasitaemia).
• -Fever (axillary temperature >37.5oC) or history of fever in the last 48 hours.
• -Able to participate in the trial and comply with the clinical trial protocol
• -Written informed consent to participate in trial; verbal consent in presence of literate witness is required for illiterate patients, and written consent from parents/guardian for children below age of consent

Exclusion Criteria:

• Pregnancy or lactation

  • -Inability to tolerate oral treatment
  • -Signs/symptoms indicative of severe/complicated malaria or warning signs requiring parenteral treatment
  • -Known hypersensitivity or allergy to artemisinin derivatives
  • -Serious underlying disease (cardiac, renal or hepatic)
  • -Parasitaemia >4%

Indonesia, Papua
      SP9 & SP12 Public Health- Malaria control clinics, Timika,  Papua,  Indonesia

Study chairs or principal investigators

Emiliana Tjitre, PhD,  Principal Investigator,  NIHRD   

Study ID Numbers:  Timika_FP_VP; Wellcome Trust ME028458MES
Last Updated:  September 10, 2005
Record first received:  September 7, 2005
ClinicalTrials.gov Identifier:  NCT00157859
Health Authority: Australia: Human Research Ethics Committee
ClinicalTrials.gov processed this record on 2005-09-13